Bloomberg reports that, according to the University of Oxford, the recent adverse event that prompted a suspension of the large-scale Phase 3 clinical trial evaluating COVID-19 vaccine candidate ChAdOx1 [dubbed AZD1222 by licensee AstraZeneca (AZN +0.2%)] was unlikely related to the shot.

The trial was voluntarily paused last week after a participant in the UK developed serious neurological symptoms.



Source link